IDiyas

For the Inventor, By the Inventor

Vaucluse, Australia

Charles Reay Mackay

USPTO Granted Patents = 14 

Average Co-Inventor Count = 1.5

ph-index = 6

Forward Citations = 110(Granted Patents)


Location History:

  • Vaucluse, AU (2011 - 2020)
  • Clayton, AU (2021)

Company Filing History:

goldMedal6 out of 6 
 
G2 Inflammation Pty Ltd
 patents
silverMedal4 out of 371 
 
Beijing University of Technology
 patents
bronzeMedal3 out of 3 
 
G2 Therapies Ltd
 patents
4. 1 out of 26 
 
Garvan Institute of Medical Research
 patents

Years Active: 2011-2021

Loading Chart...
14 patents (USPTO):Explore Patents
1. 11053319 - CXCR2 antibodies and uses thereof (2021-07-06),
2. 10940212 - IL-21 agonist antibodies and methods of treatment using same (2021-03-09),
3. 10787510 - Methods of treating cancer using an IL-21 agonist (2020-09-29),
4. 10077301 - IL-21 binding proteins (2018-09-18),
5. 8808701 - Methods of inhibiting the interaction of C5aR with C5a with anti-C5aR antibodies (2014-08-19),
6. 8673305 - Methods of treatment with antibodies against the extracellular loops of C5aR (2014-03-18),
7. 8361468 - Humanized anti-C5aR antibodies (2013-01-29),
8. 8337852 - Anti-C5aR antibodies with improved properties (2012-12-25),
9. 8268972 - Humanized anti-C5aR antibodies (2012-09-18),
10. 8236933 - Modified animal lacking functional PYY gene, monoclonal antibodies that bind PYY isoforms and uses therefor (2012-08-07),
11. 8221757 - Monoclonal antibodies against extracellular loops of C5aR (2012-07-17),
12. 8084024 - Method for producing antibodies (2011-12-27),
13. 8071839 - Transgenic mouse comprising a polynucleotide encoding human or humanized C5aR and methods of production and use (2011-12-06),
14. 8071096 - Anti-C5aR antibodies and uses thereof (2011-12-06),

Title: The Innovations of Charles Reay Mackay

Introduction

Charles Reay Mackay is a prominent inventor based in Vaucluse, Australia. He has made significant contributions to the field of biotechnology, particularly in the development of therapeutic antibodies. With a total of 14 patents to his name, Mackay's work has had a substantial impact on medical research and treatment.

Latest Patents

Mackay's latest patents include groundbreaking inventions such as CXCR2 antibodies and their uses. This invention relates to CXCR2, focusing on antibodies and related fragments that bind to CXCR2. It also covers the production of these antibodies and fragments, as well as their application in the detection and therapy of various conditions. Another notable patent is for IL-21 agonist antibodies and methods of treatment using the same. This invention pertains to IL-21, detailing antibodies and related fragments that bind to IL-21, their production, and their use in detecting and treating conditions, particularly in inflammation, infection, and oncology.

Career Highlights

Throughout his career, Mackay has worked with several notable organizations. He has been associated with G2 Inflammation Pty Ltd, where he contributed to innovative research and development. Additionally, he has collaborated with Beijing University of Technology, further expanding his influence in the field of biotechnology.

Collaborations

Mackay has worked alongside esteemed colleagues such as Peter Whitfeld and David Georges Zahra. Their collaborative efforts have led to advancements in therapeutic applications and research methodologies.

Conclusion

Charles Reay Mackay's contributions to the field of biotechnology through his patents and collaborations highlight his role as a leading inventor. His work continues to influence medical research and therapeutic development, showcasing the importance of innovation in addressing health challenges.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…